Cergentis marks Solvias' second acquisition since partnering with health care investors Water Street Healthcare Partners and JLL Partners in 2020. The Switzerland based company has recruited industry leaders to join its board and commenced a program to significantly upgrade and expand its information technology platform and infrastructure to support its plans for global expansion.

With global sales of cell & gene therapies projected to accelerate at a 63% compound annual growth rate, more researchers require sophisticated solutions to validate the safety & efficacy of these advanced new therapies. Cergentis enables Solvias to provide customers with proprietary technology and knowledge steeped in fast-evolving genomic techniques that support effective decision-making and R&D program design.